Fentanyl
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Fentanyl
- Fentanyl: From Severe Pain Management to Nephrogenic Syndrome of Inappropriate Antidiuresis
Using no additional skill — this is a direct report-generation task with a fully specified template, not something requiring brainstorming, debugging, or a domain skill.
I’m using predicted_indications[0] (rank 1, “nephrogenic syndrome of inappropriate antidiuresis”, the highest-scoring TxGNN prediction) as the primary subject per the template’s field-extraction rules. Its scoring block was left as "pending" in the pack, so I derived Evidence Level myself from the actual evidence counts (0 trials, 0 literature → L5) and set the recommendation to Hold consistent with that level and with rank 2’s own Hold outcome under identical evidence conditions.
Fentanyl: From Severe Pain Management to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Fentanyl is a well-established potent opioid analgesic, most familiar in the UK for severe and breakthrough pain management and anaesthesia. The TxGNN model predicts a possible link to Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model score alone. (A second candidate indication, Tourette syndrome, was also flagged with a similarly high score and was independently assessed as Hold due to lack of mechanistic plausibility.)
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (data gap); Fentanyl is internationally established for severe/breakthrough pain management and anaesthesia |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate is currently a data gap. Based on what is known, Fentanyl is a high-potency synthetic μ-opioid receptor agonist; its efficacy in severe pain control and anaesthesia is well established, but this pharmacology has no documented mechanistic connection to NSIAD.
NSIAD is a rare, typically hereditary condition caused by gain-of-function mutations in the vasopressin V2 receptor, which produces receptor activation and water retention independent of circulating antidiuretic hormone (ADH) levels. Opioids such as fentanyl are generally known to suppress ADH release rather than act on the V2 receptor itself, so there is no obvious pharmacological pathway linking fentanyl to a receptor-level, ADH-independent disorder like NSIAD.
The repurposing_rationale for this candidate was left as "pending" in the evidence pack, meaning no mechanistic linkage or similarity-to-original-indication analysis has actually been produced yet. This prediction should therefore be read as a raw knowledge-graph association rather than a mechanistically supported hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisation records are currently available for Fentanyl in this evidence pack (market status: Not marketed; 0 licences on record).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: the label warnings/contraindications field for this drug is flagged as a Blocking data gap in the evidence pack (unable to complete initial safety screening), and the drug interaction check returned no result (not_found). Given Fentanyl’s known high-risk profile (opioid dependence, respiratory depression, extensive CYP3A4-mediated interactions), this gap should be closed before any further evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score (L5 evidence, no trials or literature), the mechanistic rationale is explicitly unfilled/pending, and a Blocking-severity data gap in label warnings and contraindications means this candidate cannot even complete initial safety screening (S1). Combined with Fentanyl’s inherently high-risk safety profile as a potent opioid, there is no basis to proceed at this time.
To proceed, the following is needed:
- MHRA/manufacturer SmPC warnings and contraindications (currently Blocking gap)
- Mechanism-of-action data confirming or refuting a plausible pathway to NSIAD
- A completed mechanistic rationale and similarity-to-original-indication analysis (currently marked “pending”)
- Any preclinical, case-report, or observational evidence, however limited, to move beyond pure model prediction
- Drug interaction data (current query returned no result)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.